KDNY News and Press, Chinook Therapeutics Inc Com From 06/12/23

Chinook Therapeutics, Inc. (NASDAQ: KDNY) is one of today's top gainers. The company's shares are currently up 58.38% on the day to $37.99. Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines fo...

2023-06-12 13:17:32 ET Gainers: Asset Entities ( ASST ) +95% . Jin Medical International ( ZJYL ) +68% . Chinook Therapeutics ( KDNY ) +58% . Infobird ( IFBD ) +42% . Micromobility.com ( MCOM ) +39% . Freightos Limited ( CR...

2023-06-12 12:51:14 ET Shares of Chinook Therapeutics (NASDAQ: KDNY) were up more than 57% early Monday afternoon after the healthcare company agreed to a $3.2 billion buyout offer from Novartis . Chinook is a clinical-stage biotech company that specializes in treati...

2023-06-12 10:43:42 ET Kidney disease drug developer Chinook Therapeutics ( KDNY ) added ~56% on Monday after announcing a $3.5B buyout deal with Novartis ( NVS ), sending the shares of its rival Vera Therapeutics ( NASDAQ: VERA ) sharply higher. Per the terms, the S...

2023-06-12 10:07:43 ET Investors appeared to be in a good mood on Monday morning. Based on stock index futures, it was likely that major market benchmarks would hold onto their gains from last week and even make modest moves higher. The Nasdaq Composite seemed particularly well position...

2023-06-12 02:56:04 ET Novartis ( NVS ) will acquire biopharmaceutical company, Chinook Therapeutics ( KDNY ) for $40 per share in cash, or a total of $3.2B. This offer represents a premium of 83% to Chinook’s 60-day volume-weighted average stock price and 67% to...

Novartis to acquire Chinook for $40 per share in cash, with potential to receive up to an additional $4 per share in cash through contingent value rights, for a total equity value of up to approximately $3.5 billion Chinook’s diversified pipeline of potentially best-in-class pr...

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Chinook To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - June 8, 2023) - Faruqi & Faruqi, LLP, a leading national securities law firm, is inve...

2023-05-30 06:54:18 ET Summary Patient and Prescriber Uptick: Despite Q1 2023's slightly disappointing earnings, Tarpeyo saw robust growth in new patient enrollments and prescriber numbers. Competitive Edge: Recent Phase 3 DUPLEX FSGS readout from Travere showing non-stat signific...

SAN FRANCISCO, May 22, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Chinook Therapeutics, Inc. (NASDAQ: KDNY) investors who suffered substantial losses to submit your losses now . Visit: www.hbsslaw.com/investor-fraud/KDNY Contact An Attorney Now: KDNY@hbsslaw.com ...